Thai-made Favipiravir in human trials ahead of production
Thailand now has capacity to manufacture the Covid-9 medication Favipiravir on an industrial scale, the Government Pharmaceutical Organisation (GPO) said on Thursday.
Human trials are underway to test the Thai-made Favipiravir against the version available on the international market, said GPO deputy managing director Dr Sirikul Matevelungsun. The trial is scheduled to submit its findings for registration of the drug by the Food and Drug Administration (FDA) in June or July.
The GPO will be able to produce Favipiravir tablets as soon as they are listed in the Thai drug register.
Dr Sirikul said the GPO has the capacity to meet strong demand for the drug, which is used to treat serious Covid-19 symptoms such as pneumonia.
Meanwhile, the Government Pharmaceutical Organisation (GPO) is collaborating with the National Science and Technology Development Agency (NSTDA) and PTT Co Ltd to expand production of raw materials for Favipiravir and other essential pharmaceuticals to an industrial scale.
The aim is create stability, sustainability and self-reliance in medicine for Thailand.
